HOMEAssistant Professor Yasuteru Sakurai

Faculty

Assistant Professor Yasuteru Sakurai

Speciality / Research theme / Keywords
Virology, Emerging viral diseases, BSL-4, Antiviral drugs
Supervision
Doctoral ProgrammeMasters Programme

Qualifications

Ph.D. (Life science)

Personal/work Web page addresses

http://www.tm.nagasaki-u.ac.jp/emerging/

Research gate or Linked-in account links

https://www.researchgate.net/profile/Yasuteru-Sakurai-2

Affiliation(s)

Department of Emerging Infectious Diseases, Institute of Tropical Medicine, Nagasaki University
Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University

Background

  • 2001-2005 : Faculty of Science, Kyoto University
  • 2005-2010 : Graduate School of Biostudies, Kyoto University
  • 2010-2012 : Postdoctoral Researcher, Institute for Virus Research, Kyoto University
  • 2012-2016 : Postdoctoral Researcher, Texas Biomedical Research Institute, USA
  • 2017 : Staff Scientist, Texas Biomedical Research Institute, USA
  • 2017-2018 : Project Researcher, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University
  • 2018- : Assistant Professor, Institute of Tropical Medicine / National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University

Research

Analysis of molecular mechanisms how highly pathogenic viruses replicate in the host cells, development of rapid and efficient screening systems to quantify viral infection, development of antiviral drugs

The country/countries where you work currently

Japan

Five MOST IMPORTANT/INTERESTING recent publications

  1. Hirano M, Sakurai Y, Urata S, Kurosaki Y, Yasuda J, Yoshii K. A screen of FDA-approved drugs with minigenome identified tigecycline as an antiviral targeting nucleoprotein of Crimean-Congo hemorrhagic fever virus. Antiviral Research. 2022; 200:105276.
  2. Moni BM, Sakurai Y, Yasuda J. Ebola virus GP activates endothelial cells via host cytoskeletal signaling factors. Viruses. 2022; 14(1):142.
  3. Imamura K#, Sakurai Y#, Takano E, Shibukawa R, Nishi Y, Ohta A, Shu T, Kawaguchi J, Okada S, Hoenen T, Yasuda J, Inoue H. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility. FEBS Open Bio. 2021; 11(5):1452-1464. (#equally contributed)
  4. Sakurai Y, Ngwe Tun MM, Kurosaki Y, Sakura T, Inaoka DK, Fujine K, Kita K, Morita K, Yasuda J. 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro.  Biochemical and Biophysical Research Communications. 2021; 545:203-207.
  5. Sakurai Y, Sakakibara N, Toyama M, Baba M, Davey RA. Novel amodiaquine derivatives potently inhibit Ebola virus infection. Antiviral Research. 2018;160:175-182.
PAGE TOP
HSR2024